Nanoplatform-Based Atherosclerotic Theragnostics via Targeting of Early-Stage Vulnerable Plaques
Source abstract
Abstract
Atherosclerosis, characterized by the accumulation of lipid with the high concentration of reactive oxygen species, has a profound impact on cardiovascular health. However, developing efficient treatment strategies are challenging due to the complex pathogenesis. In this work, mesoporous polydopamine nanoparticles conjugated with mannose were synthesized and employed for targeted treatment of early atherosclerosis. The surface modification of d -mannose imparts intrinsic targeting ability to the delivery system. This mesoporous polydopamine not only converts harmful superoxide anion radicals ( • O 2– ) and hydrogen peroxide (H 2 O 2 ) into harmless water and oxygen but also scavenges highly toxic hydroxyl radicals ( • OH), thereby significantly reducing intracellular ROS levels. More importantly, the system promotes lipid efflux through mild photothermal effects, significantly reducing the risk of plaque rupture. This approach combines mild photothermal therapy with reactive oxygen species (ROS) scavenging to achieve effective therapeutic outcomes.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Atherosclerosis and Cardiovascular Diseases · Galectins and Cancer Biology · Coronary Interventions and Diagnostics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Pharmaceutics
Shanghai Eighth People’s Hospital
411# Hospital, School of Medicine
Shanghai University
College of Pharmacology
Fujian University of Traditional Chinese Medicine
Department of Pharmacy, Shanghai Tianyou Hospital, School of Life Sciences and Technology
Tongji University
Funding
Jiangsu University · Fujian University of Traditional Chinese Medicine · Shanghai Municipal Health Commission · Xuhui District, Shanghai · Xuhui Health System, Shanghai
References (45)
Show source-provided references
1. 10.1038/nrcardio.2015.20310.1038/nrcardio.2015.203 ↗
2. 10.1161/CIRCULATIONAHA.123.06700310.1161/CIRCULATIONAHA.123.067003 ↗
3. 10.1093/eurheartj/ehab724.240910.1093/eurheartj/ehab724.2409 ↗
4. 10.1038/s41569-024-01075-110.1038/s41569-024-01075-1 ↗
5. 10.1161/CIRCULATIONAHA.117.03048410.1161/CIRCULATIONAHA.117.030484 ↗
6. 10.1161/CIRCRESAHA.116.30932610.1161/CIRCRESAHA.116.309326 ↗
7. 10.1016/j.tcm.2019.01.00110.1016/j.tcm.2019.01.001 ↗
8. 10.1002/advs.20230291810.1002/advs.202302918 ↗
9. 10.1002/advs.20230429410.1002/advs.202304294 ↗
10. 10.1016/j.apsb.2022.11.01410.1016/j.apsb.2022.11.014 ↗
11. 10.1002/adhm.20230361210.1002/adhm.202303612 ↗
12. 10.1016/j.atherosclerosis.2016.07.77710.1016/j.atherosclerosis.2016.07.777 ↗
13. 10.1016/j.pacs.2021.10026110.1016/j.pacs.2021.100261 ↗
14. 10.1002/advs.20220241610.1002/advs.202202416 ↗
15. 10.1016/j.cej.2024.14988210.1016/j.cej.2024.149882 ↗
16. 10.1093/rb/rbad03110.1093/rb/rbad031 ↗
17. 10.1016/j.bioactmat.2022.01.01310.1016/j.bioactmat.2022.01.013 ↗
18. 10.1038/ni.200110.1038/ni.2001 ↗
19. 10.1161/CIRCRESAHA.114.30215310.1161/CIRCRESAHA.114.302153 ↗
20. 10.1161/CIRCRESAHA.114.30272110.1161/CIRCRESAHA.114.302721 ↗
21. 10.1016/j.immuni.2013.06.00910.1016/j.immuni.2013.06.009 ↗
22. 10.1021/acs.biomac.4c0024110.1021/acs.biomac.4c00241 ↗
23. 10.1038/nature1014610.1038/nature10146 ↗
24. 10.1002/adma.20211066010.1002/adma.202110660 ↗
25. 10.1002/adhm.20230264010.1002/adhm.202302640 ↗
26. 10.1002/adma.20240355710.1002/adma.202403557 ↗
27. 10.1002/adma.20241222710.1002/adma.202412227 ↗
28. 10.1016/j.cej.2024.15420510.1016/j.cej.2024.154205 ↗
29. 10.1016/j.matdes.2023.11185810.1016/j.matdes.2023.111858 ↗
30. 10.1002/adfm.20241011310.1002/adfm.202410113 ↗
31. 10.1016/j.ccr.2024.21604310.1016/j.ccr.2024.216043 ↗
32. 10.1007/s13346-022-01265-910.1007/s13346-022-01265-9 ↗
33. 10.1038/nm.343710.1038/nm.3437 ↗
34. 10.1016/j.nantod.2021.10135110.1016/j.nantod.2021.101351 ↗
35. 10.1016/j.jconrel.2024.02.03910.1016/j.jconrel.2024.02.039 ↗
36. 10.1021/acsanm.3c0285110.1021/acsanm.3c02851 ↗
37. 10.1016/j.colsurfb.2025.11490010.1016/j.colsurfb.2025.114900 ↗
38. 10.1016/j.jconrel.2019.02.02310.1016/j.jconrel.2019.02.023 ↗
39. 10.1016/j.biomaterials.2007.12.02510.1016/j.biomaterials.2007.12.025 ↗
40. 10.1016/j.redox.2021.10215610.1016/j.redox.2021.102156 ↗
41. 10.3390/biomedicines806016610.3390/biomedicines8060166 ↗
42. 10.1021/acs.biomac.0c0123810.1021/acs.biomac.0c01238 ↗
43. 10.1016/j.mtbio.2025.10224210.1016/j.mtbio.2025.102242 ↗
44. 10.1038/s41467-020-19664-210.1038/s41467-020-19664-2 ↗
45. 10.1186/s40659-021-00335-510.1186/s40659-021-00335-5 ↗